glucose test

FRIDAY, Oct. 27, 2017 (HealthDay News) -- Incretin treatment appears to improve non-ST-elevation myocardial infarction (NSTEMI) outcomes in patients with type 2 diabetes and non-obstructive coronary artery stenosis (NOCS), according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Raffaele Marfella, M.D., Ph.D., from Università degli Studi della Campania in Italy, and colleagues compared the 12-month prognosis of individuals with NOCS-diabetes (20 to 49 percent luminal stenosis) with first NSTEMI with that of individuals without diabetes. They also investigated the prognosis of NSTEMI-NOCS diabetes patients previously treated with incretin-based therapy with a matched cohort of NSTEMI-NOCS patients never treated with incretin. Patients with diabetes were characterized as current incretin users (six months, GLP-1 agonists or DPP-4 inhibitors) and never incretin users.

The researchers found that all-cause death, cardiac death, readmission for acute coronary syndrome, and heart failure were higher in patients with diabetes than those without diabetes. Among the diabetes patients, current incretin users had a significantly lower rate of all-cause death, cardiac death, and readmission for ACS through the 12-month period.

"In type 2 diabetic patients with NOCS-NSTEMI, we observed higher incidence of one-year mortality, and adverse cardiovascular outcomes, as compared to non-diabetic NOCS-NSTEMI patients. In diabetic patients, never-incretin-users have worse prognosis as compared to current-incretin-users," conclude the authors.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

Updated on May 29, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ